Aravive Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1375
- Today's High:
- $0.1425
- Open Price:
- $0.1408
- 52W Low:
- $0.58
- 52W High:
- $2.227
- Prev. Close:
- $0.148
- Volume:
- 2379373
Company Statistics
- Market Cap.:
- $122.05 million
- Book Value:
- 0.493
- Revenue TTM:
- $8.65 million
- Operating Margin TTM:
- -747.34%
- Gross Profit TTM:
- $-30099000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -67.88%
- Return on Equity TTM:
- -173.41%
Company Profile
Aravive Inc had its IPO on 2014-03-21 under the ticker symbol ARAV.
The company operates in the Healthcare sector and Biotechnology industry. Aravive Inc has a staff strength of 23 employees.
Stock update
Shares of Aravive Inc opened at $0.14 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.14 - $0.14, and closed at $0.14.
This is a -4.39% slip from the previous day's closing price.
A total volume of 2,379,373 shares were traded at the close of the day’s session.
In the last one week, shares of Aravive Inc have increased by +1.07%.
Aravive Inc's Key Ratios
Aravive Inc has a market cap of $122.05 million, indicating a price to book ratio of 7.2785 and a price to sales ratio of 11.4147.
In the last 12-months Aravive Inc’s revenue was $8.65 million with a gross profit of $-30099000 and an EBITDA of $-63738000. The EBITDA ratio measures Aravive Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aravive Inc’s operating margin was -747.34% while its return on assets stood at -67.88% with a return of equity of -173.41%.
In Q3, Aravive Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 105.5%.
Aravive Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aravive Inc’s profitability.
Aravive Inc stock is trading at a EV to sales ratio of 9.9715 and a EV to EBITDA ratio of -1.3529. Its price to sales ratio in the trailing 12-months stood at 11.4147.
Aravive Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $42.22 million
- Total Liabilities
- $23.73 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Aravive Inc ended 2024 with $42.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $42.22 million while shareholder equity stood at $15.04 million.
Aravive Inc ended 2024 with $0 in deferred long-term liabilities, $23.73 million in other current liabilities, 3000.00 in common stock, $-587002000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $27.90 million and cash and short-term investments were $27.90 million. The company’s total short-term debt was $2,220,000 while long-term debt stood at $0.
Aravive Inc’s total current assets stands at $37.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $6.00 million compared to accounts payable of $8.82 million and inventory worth $0.
In 2024, Aravive Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aravive Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.14
- 52-Week High
- $2.227
- 52-Week Low
- $0.58
- Analyst Target Price
- $11.75
Aravive Inc stock is currently trading at $0.14 per share. It touched a 52-week high of $2.227 and a 52-week low of $2.227. Analysts tracking the stock have a 12-month average target price of $11.75.
Its 50-day moving average was $0.75 and 200-day moving average was $1.46 The short ratio stood at 9.72 indicating a short percent outstanding of 0%.
Around 4922.4% of the company’s stock are held by insiders while 2552.7% are held by institutions.
Frequently Asked Questions About Aravive Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.